Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review

Abstract The availability of immune-checkpoint inhibitors (ICI) in the last decade has resulted in a paradigm shift in certain areas of oncology. Patients can be treated either by a monotherapy of anti-CTLA-4 (tremelimumab or ipilimumab), anti-PD-1 (nivolumab or pembrolizumab), or anti-PD-L1 (avelum...

Full description

Bibliographic Details
Main Authors: Szonja Anna Kovács, Balázs Győrffy
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Journal of Translational Medicine
Subjects:
PD-1
PD-L1
CTLA-4
Survival
Response
Clinical data
Online Access:https://doi.org/10.1186/s12967-022-03409-4

Internet

https://doi.org/10.1186/s12967-022-03409-4

Similar Items